REPLIGEN CORP Deferred Revenue, Revenue Recognized
REPLIGEN CORP (RGEN) reported Deferred Revenue, Revenue Recognized of $2.12 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2017-02-23
- REPLIGEN CORP deferred revenue, revenue recognized for fiscal 2016 was $2.12M.
| Period end | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|
| 2016-12-31 | $2.12M 10-K · filed 2017-02-23 | ||
| 2016-09-30 | $2.12M 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | $2.12M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |